ArticleJGH open : an open access journal of gastroenterology and hepatology2026
Cost-Effectiveness and Efficacy of Biodegradable Pancreatic Stents for Preventing Post-ERCP Pancreatitis: A Retrospective Multi-Center Study.
Article in JGH open : an open access journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) occurs in up to 10% of cases. Prophylactic pancreatic stenting reduces PEP risk; however, plastic stents frequently require an additional procedure for removal, increasing cost and patient burden. Biodegradable pancreatic stents negate the need for retrieval, but data on cost-effectiveness and clinical outcomes remain limited. Methods: We conducted a two-center retrospective cohort study of adults undergoing ERCP with biodegradable pancreatic stent placement for PEP prophylaxis between January 2021 and August 2025. Demographic, procedural, and clinical data were collected. The primary outcome was per-patient cost difference between patient journeys utilizing biodegradable and plastic stenting. Secondary outcomes included PEP incidence, technical success, and stent usability data. Results: A total of 5086 ERPCs were performed during the study period, and 111 ERCPs with biodegradable stents inserted were analyzed (mean age 62 years; 57% female; 39% rural). Technical success was 98%. The mean cost difference per patient favored biodegradable stents by AUD$393 (95% CI 149-63, Conclusion: Biodegradable pancreatic stent placement is technically safe, effective, and associated with significant cost savings and reduced patient/healthcare burden by negating the need for further procedures. Observed PEP rates were consistent with those reported in high-risk cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.